| Year |
Citation |
Score |
| 2020 |
Santich BH, Cheal SM, Ahmed M, McDevitt MR, Ouerfelli O, Yang G, Veach D, Fung EK, Patel M, Burnes Vargas D, Malik AA, Guo H, Zanzonico PB, Monette S, Michel AO, et al. A Self-Assembling and DisAssembling (SADA) bispecific antibody (BsAb) platform for curative 2-step pre-targeted radioimmunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32958698 DOI: 10.1158/1078-0432.Ccr-20-2150 |
0.304 |
|
| 2020 |
Bicak M, Lückerath K, Kalidindi T, Phelps ME, Strand SE, Morris MJ, Radu CG, Damoiseaux R, Peltola MT, Peekhaus N, Ho A, Veach D, Malmborg Hager AC, Larson SM, Lilja H, et al. Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy. Proceedings of the National Academy of Sciences of the United States of America. PMID 32532924 DOI: 10.1073/Pnas.1918744117 |
0.338 |
|
| 2020 |
Krebs S, Veach DR, Carter LM, Grkovski M, Fornier M, Mauro MJ, Voss MH, Danila DC, Burnazi E, Null M, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Weber WA, et al. First-in-Human Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted Positron Emission Tomography. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32169913 DOI: 10.2967/Jnumed.119.234864 |
0.3 |
|
| 2018 |
McDevitt MR, Thorek DLJ, Hashimoto T, Gondo T, Veach DR, Sharma SK, Kalidindi TM, Abou DS, Watson PA, Beattie BJ, Timmermand OV, Strand SE, Lewis JS, Scardino PT, Scher HI, et al. Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nature Communications. 9: 1629. PMID 29691406 DOI: 10.1038/S41467-018-04107-W |
0.328 |
|
| 2018 |
Cheal SM, Ruan S, Veach DR, Longo VA, Punzalan BJ, Wu J, Fung EK, Kelly MP, Kirshner JR, Giurleo JT, Ehrlich G, Han AQ, Thurston G, Olson WC, Zanzonico PB, et al. ImmunoPET imaging of endogenous and transfected prolactin receptor tumor xenografts. Molecular Pharmaceutics. PMID 29684277 DOI: 10.1021/Acs.Molpharmaceut.7B01133 |
0.329 |
|
| 2017 |
Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, Vargas HA, Schöder H, Humm JL, Fine SW, Lewis JS, Solomon SB, Osborne JR, Veach D, Sawyers CL, et al. Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. Jama Oncology. e173588. PMID 29121144 DOI: 10.1001/Jamaoncol.2017.3588 |
0.315 |
|
| 2017 |
Pankov D, Sjöström L, Kalidindi T, Lee SG, Sjöström K, Gardner R, McDevitt MR, O'Reilly R, Thorek DLJ, Larson SM, Veach D, Ulmert D. In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME). Oncotarget. 8: 65917-65931. PMID 29029482 DOI: 10.18632/Oncotarget.19579 |
0.326 |
|
| 2017 |
Bosbach B, Rossi F, Yozgat Y, Loo J, Zhang JQ, Berrozpe G, Warpinski K, Ehlers I, Veach D, Kwok A, Manova K, Antonescu CR, DeMatteo RP, Besmer P. Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor. Proceedings of the National Academy of Sciences of the United States of America. PMID 28923937 DOI: 10.1073/Pnas.1711449114 |
0.403 |
|
| 2016 |
Thorek DL, Watson PA, Lee SG, Ku AT, Bournazos S, Braun K, Kim K, Sjöström K, Doran MG, Lamminmäki U, Santos E, Veach D, Turkekul M, Casey E, Lewis JS, et al. Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. Science Translational Medicine. 8: 367ra167. PMID 27903863 DOI: 10.1126/Scitranslmed.Aaf2335 |
0.347 |
|
| 2016 |
Pandit-Taskar N, Veach DR, Fox JJ, Scher HI, Morris MJ, Larson SM. Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 57: 73S-78S. PMID 27694177 DOI: 10.2967/Jnumed.115.170134 |
0.305 |
|
| 2016 |
Behling K, DiGialleonardo V, Maguire WF, Heeb LE, Hassan IF, Veach DR, Keshari KR, Gutin PH, Scheinberg DA, McDevitt MR. Remodelling the vascular microenvironment of glioblastoma with alpha-particles. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27261519 DOI: 10.2967/Jnumed.116.173559 |
0.304 |
|
| 2016 |
Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylergil V, Amir J, Chalasani S, Weber WA, Spratt DE, Veach DR, Bander NH, Larson SM, Zanzonico PB, Osborne JR. Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. Ejnmmi Research. 6: 7. PMID 26801327 DOI: 10.1186/S13550-016-0164-0 |
0.333 |
|
| 2014 |
Kim TS, Cavnar MJ, Cohen NA, Sorenson EC, Greer JB, Seifert AM, Crawley MH, Green BL, Popow R, Pillarsetty N, Veach DR, Ku AT, Rossi F, Besmer P, Antonescu CR, et al. Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2350-62. PMID 24583793 DOI: 10.1158/1078-0432.Ccr-13-3033 |
0.365 |
|
| 2012 |
Benezra M, Hambardzumyan D, Penate-Medina O, Veach DR, Pillarsetty N, Smith-Jones P, Phillips E, Ozawa T, Zanzonico PB, Longo V, Holland EC, Larson SM, Bradbury MS. Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model. Neoplasia (New York, N.Y.). 14: 1132-43. PMID 23308046 DOI: 10.1593/Neo.121750 |
0.333 |
|
| 2012 |
Bosbach B, Deshpande S, Rossi F, Shieh JH, Sommer G, de Stanchina E, Veach DR, Scandura JM, Manova-Todorova K, Moore MA, Antonescu CR, Besmer P. Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor. Proceedings of the National Academy of Sciences of the United States of America. 109: E2276-83. PMID 22652566 DOI: 10.1073/Pnas.1115240109 |
0.325 |
|
| 2012 |
Dunphy MP, Zanzonico P, Veach D, Somwar R, Pillarsetty N, Lewis J, Larson S. Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 14: 25-31. PMID 21161687 DOI: 10.1007/S11307-010-0462-2 |
0.34 |
|
| 2011 |
Zhou G, Sylvester JE, Wu D, Veach DR, Kron SJ. A magnetic bead-based protein kinase assay with dual detection techniques. Analytical Biochemistry. 408: 5-11. PMID 20807497 DOI: 10.1016/J.Ab.2010.08.034 |
0.341 |
|
| 2010 |
Rossi F, Yozgat Y, de Stanchina E, Veach D, Clarkson B, Manova K, Giancotti FG, Antonescu CR, Besmer P. Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Molecular Cancer Research : McR. 8: 1271-83. PMID 20736294 DOI: 10.1158/1541-7786.Mcr-10-0065 |
0.408 |
|
| 2010 |
Mand MR, Wu D, Veach DR, Kron SJ. Cell treatment and lysis in 96-well filter-bottom plates for screening Bcr-Abl activity and inhibition in whole-cell extracts. Journal of Biomolecular Screening. 15: 434-40. PMID 20237206 DOI: 10.1177/1087057110363307 |
0.404 |
|
| 2010 |
Doubrovin M, Kochetkova T, Santos E, Veach DR, Smith-Jones P, Pillarsetty N, Balatoni J, Bornmann W, Gelovani J, Larson SM. (124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 121-9. PMID 20048131 DOI: 10.2967/Jnumed.109.066126 |
0.385 |
|
| 2010 |
Benezra M, Hambardzumyan D, Penate-Medina O, Veach DR, Pillarsetty N, Smith-Jones P, Zanzonico P, Longo VA, Holland EC, Larson SM, Bradbury MS. Abstract LB-299: F-dasatinib inhibits glioma cell proliferation and alters expression of PDGFR signaling pathway intermediates in PDGFR-overexpressing glioma models Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-299 |
0.405 |
|
| 2009 |
Antczak C, Veach DR, Ramirez CN, Minchenko MA, Shum D, Calder PA, Frattini MG, Clarkson B, Djaballah H. Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorganic & Medicinal Chemistry Letters. 19: 6872-6. PMID 19889540 DOI: 10.1016/J.Bmcl.2009.10.085 |
0.401 |
|
| 2009 |
Guo T, Hajdu M, Agaram NP, Shinoda H, Veach D, Clarkson BD, Maki RG, Singer S, Dematteo RP, Besmer P, Antonescu CR. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6862-70. PMID 19861442 DOI: 10.1158/1078-0432.Ccr-09-1315 |
0.358 |
|
| 2008 |
Wu D, Mand MR, Veach DR, Parker LL, Clarkson B, Kron SJ. A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates. Analytical Biochemistry. 375: 18-26. PMID 18194660 DOI: 10.1016/J.Ab.2007.12.023 |
0.412 |
|
| 2007 |
Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. The Journal of Clinical Investigation. 117: 3846-56. PMID 18060032 DOI: 10.1172/Jci31871 |
0.344 |
|
| 2007 |
Veach DR, Namavari M, Pillarsetty N, Santos EB, Beresten-Kochetkov T, Lambek C, Punzalan BJ, Antczak C, Smith-Jones PM, Djaballah H, Clarkson B, Larson SM. Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. Journal of Medicinal Chemistry. 50: 5853-7. PMID 17956080 DOI: 10.1021/Jm070342G |
0.425 |
|
| 2007 |
Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG, Schwartz GK, Veach D, Clarkson BD, Singer S, DeMatteo RP, Besmer P, Antonescu CR. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4874-81. PMID 17699867 DOI: 10.1158/1078-0432.Ccr-07-0484 |
0.395 |
|
| 2007 |
Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, Besmer P, Jungbluth A, Gimbel M, Chen CT, Veach D, Clarkson BD, Paty PB, Weiser MR. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. International Journal of Cancer. 121: 257-64. PMID 17372901 DOI: 10.1002/Ijc.22681 |
0.352 |
|
| 2006 |
Liang X, Hajivandi M, Veach D, Wisniewski D, Clarkson B, Resh MD, Pope RM. Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. Proteomics. 6: 4554-64. PMID 16858728 DOI: 10.1002/Pmic.200600109 |
0.383 |
|
| 2006 |
Azam M, Nardi V, Shakespeare WC, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, Daley GQ. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proceedings of the National Academy of Sciences of the United States of America. 103: 9244-9. PMID 16754879 DOI: 10.1073/Pnas.0600001103 |
0.425 |
|
| 2006 |
Wendel HG, De Stanchina E, Cepero E, Ray S, Emig M, Fridman JS, Veach DR, Bornmann WG, Clarkson B, McCombie WR, Kogan SC, Hochhaus A, Lowe SW. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition Proceedings of the National Academy of Sciences of the United States of America. 103: 7444-7449. PMID 16651519 DOI: 10.1073/Pnas.0602402103 |
0.428 |
|
| 2006 |
Doubrovin M, Beresten T, Veach D, Namavari M, Balatoni J, Bornmann W, Guelovani J, Larson S. Detection of BCR-ABL expression in human CML model using radiolabeled analogue of ABL-protein kinase inhibitor and positron-emission tomography (PET) Biology of Blood and Marrow Transplantation. 12: 17. DOI: 10.1016/J.Bbmt.2005.11.056 |
0.34 |
|
| 2005 |
Reeves PM, Bommarius B, Lebeis S, McNulty S, Christensen J, Swimm A, Chahroudi A, Chavan R, Feinberg MB, Veach D, Bornmann W, Sherman M, Kalman D. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nature Medicine. 11: 731-9. PMID 15980865 DOI: 10.1038/Nm1265 |
0.369 |
|
| 2005 |
Veach DR, Namavari M, Beresten T, Balatoni J, Minchenko M, Djaballah H, Finn RD, Clarkson B, Gelovani JG, Bornmann WG, Larson SM. Synthesis and in vitro examination of [124I]-, [ 125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors Nuclear Medicine and Biology. 32: 313-321. PMID 15878500 DOI: 10.1016/J.Nucmedbio.2005.01.008 |
0.374 |
|
| 2005 |
Mack ET, Birzniece D, Veach DR, Coyle W, Wilson RM. DNA photocleavage and biological activity of a pyrene dihydrodioxin. Bioorganic & Medicinal Chemistry Letters. 15: 2173-6. PMID 15808491 DOI: 10.1016/J.Bmcl.2005.02.003 |
0.602 |
|
| 2005 |
Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia Blood. 105: 3995-4003. PMID 15657179 DOI: 10.1182/Blood-2004-09-3534 |
0.364 |
|
| 2005 |
von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sänger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood. 105: 1652-9. PMID 15459011 DOI: 10.1182/Blood-2004-06-2445 |
0.355 |
|
| 2005 |
Azam M, Nardi V, Shakespear WC, Latek RR, Veach D, Clarckson B, Bohacheck R, Sawyer TK, Daley GQ. BCR-ABL Kinase Dynamics and Drug Resistance. Blood. 106: 1996-1996. DOI: 10.1182/Blood.V106.11.1996.1996 |
0.383 |
|
| 2004 |
Deng X, Hofmann ER, Villanueva A, Hobert O, Capodieci P, Veach DR, Yin X, Campodonico L, Glekas A, Cordon-Cardo C, Clarkson B, Bornmann WG, Fuks Z, Hengartner MO, Kolesnick R. Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation. Nature Genetics. 36: 906-12. PMID 15273685 DOI: 10.1038/Ng1396 |
0.353 |
|
| 2004 |
Swimm A, Bommarius B, Li Y, Cheng D, Reeves P, Sherman M, Veach D, Bornmann W, Kalman D. Enteropathogenic Escherichia coli use redundant tyrosine kinases to form actin pedestals. Molecular Biology of the Cell. 15: 3520-9. PMID 15155808 DOI: 10.1091/Mbc.E04-02-0093 |
0.378 |
|
| 2004 |
Bubnoff Nv, Veach DR, Kuip Hvd, Aulitzky WE, Saenger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J. A cell-based screening method for resistance of Bcr-Abl positive leukemia identifies the mutation pattern for an alternative abl kinase inhibitor. Blood. 104: 558-558. DOI: 10.1182/Blood.V104.11.558.558 |
0.393 |
|
| 2003 |
von Bubnoff N, Veach DR, Miller WT, Li W, Sänger J, Peschel C, Bornmann WG, Clarkson B, Duyster J. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Research. 63: 6395-404. PMID 14559829 |
0.316 |
|
| 2003 |
Tanis KQ, Veach D, Duewel HS, Bornmann WG, Koleske AJ. Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Molecular and Cellular Biology. 23: 3884-96. PMID 12748290 DOI: 10.1128/Mcb.23.11.3884-3896.2003 |
0.386 |
|
| 2003 |
Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J. Structural basis for the autoinhibition of c-Abl tyrosine kinase Cell. 112: 859-871. PMID 12654251 DOI: 10.1016/S0092-8674(03)00194-6 |
0.333 |
|
| 2002 |
Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B, Young MA, Schindler T, Bornmann WG, Bertino JR, Kuriyan J, Clarkson B. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases Cancer Research. 62: 4244-4255. PMID 12154026 |
0.303 |
|
| 2002 |
Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Research. 62: 4236-43. PMID 12154025 DOI: 10.2210/Pdb1Iep/Pdb |
0.384 |
|
| 2001 |
Hofmann RM, Cotton GJ, Chang EJ, Vidal E, Veach D, Bornmann W, Muir TW. Fluorescent monitoring of kinase activity in real time: development of a robust fluorescence-based assay for Abl tyrosine kinase activity. Bioorganic & Medicinal Chemistry Letters. 11: 3091-4. PMID 11720849 DOI: 10.1016/S0960-894X(01)00650-3 |
0.354 |
|
| Show low-probability matches. |